NDAORALGRANULE
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALKINDI SPRINKLE (hydrocortisone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. Approved for the following conditions, rheumatoid arthritis, rheumatoid arthritis and 8 more indications. First approved in 2020.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALKINDI SPRINKLE is an oral granule formulation of hydrocortisone, a glucocorticoid corticosteroid that acts as a hormone receptor agonist. It is approved for treating inflammatory and autoimmune conditions including rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, ulcerative colitis, and hematologic malignancies. The drug works by suppressing immune response and reducing inflammation across multiple organ systems.
Peak7.5 years to LOE
Product is at peak lifecycle stage with no indicated competitive pressure; brand team focus is on maintaining market position and optimizing indications.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (9)
Worked on ALKINDI SPRINKLE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.